BlackRock, Inc. 13D and 13G filings for Supernus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-22 08:27 am Sale |
2025-03-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
8,197,023 14.700% |
-2,184,295 (-21.04%) |
Filing |
| 2024-01-19 2:40 pm Purchase |
2023-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
10,381,318 19.000% |
777,245 (+8.09%) |
Filing |
| 2023-01-23 3:52 pm Purchase |
2022-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
9,604,073 17.800% |
1,153,051 (+13.64%) |
Filing |
| 2022-01-27 5:14 pm Unchanged |
2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
8,451,022 15.900% |
0 (Unchanged) |
Filing |
| 2022-01-26 09:16 am Sale |
2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
8,451,022 15.900% |
-461,779 (-5.18%) |
Filing |
| 2021-01-25 4:50 pm Purchase |
2020-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
8,912,801 16.900% |
177,969 (+2.04%) |
Filing |